Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Febit Establishes US Company

Published: Tuesday, August 15, 2006
Last Updated: Tuesday, August 15, 2006
Bookmark and Share
Febit launches the GENIOM biochip system in the US.

febit biotech gmbh has announced the establishment of febit Incorporation, a Delaware Company based in Medford, Boston/USA.

febit Inc. will be supporting all operations throughout America: in the US, Canada and the Southern American countries. With its presence in the Unites States, febit enters the largest market for biochip technology worldwide.

Thus, GENIOM sales and customer support will be handled by qualified stuff on site. All team members are experienced in the US market.

The knowledge transfer required for a start of febit Inc. was achieved by several months of prior training for technical specialists and the US management.

Temporary delegation of febit biotech gmbh staff is envisaged as well. A fully equipped application laboratory is already established that will enable customers to perform hands-on tests of their applications on the GENIOM system and develop assays in cooperation with febit Inc.

In addition, febit will offer workshops featuring various GENIOM applications. Production for the Americas (Northern and Southern America) is expected to take place in close cooperation with US-based companies.

febit Inc. is directed by Claus E. Schmidt, Vice President Operations & General Manager, an entrepreneur experienced in knowledge transfer between Europe and the USA.

In addition, he contributes expertise in the field of chemical engineering. febit Inc. CEO Cord F. Stahler directs febit biotech gmbh in Heidelberg as well and is an accomplished manager in the international biomedical technology business.

The Operative Management is completed by Stefan M. Matysiak, PhD, Director Customer Care, who is primarily responsible for customer care and the applications laboratory.

He has several years of experience in research and development, working for renowned companies and institutions in the US and Germany, such as Applied Biosystems Inc. and the German Cancer Research Center.

The Supervisory Board of febit Inc. - as the one of febit biotech gmbh - is chaired by Dr. Gerald Moller, Director of HBM BioCapital Management GmbH and former president and CEO of the Boehringer Mannheim Group.

Vice Chairman of the Supervisory Board is Michael Kranich, Director of DH-Capital GmbH & Co. KG and OH-Beteiligungen GmbH & Co. KG that holds the majority of febit biotech GmbH for the Hopp family.

Dietmar Hopp, co-founder of SAP and its CEO and Chairman for many years, is the most potent single investor of the German biotech industry.

He primarily invests in young, promising companies in that business such as febit biotech gmbh. Supporting febit´s establishment on the American continent, he expands his engagement in the fastest-growing biotech market.

Establishing a US-based company is a logical step for Cord F. Stahler, CEO of febit Inc, "After a successful start of GENIOM in the European market, penetration of the US as the largest biochip market is an essential move in our marketing strategy."

"We are confident that our US customers as well will be convinced by the unique speed and flexibility of our system in microarray synthesis and analysis."

"With a highly efficient team in the country, we are able to specifically address this market and successfully expand our business there."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Geniom Technology Applied to Targeted Next-Generation Sequencing
By enabling selective targeting, the Geniom® Biochip will allow researchers to sequence individual and well defined parts of genomes
Tuesday, July 24, 2007
Febit Achieves Sales Goals
Febit successfully markets the GENIOM bioanalysis device.
Thursday, March 16, 2006
Scientific News
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Discovering the First Farmers
Genetic analyses reveal a collection of highly distinct groups in the Near East and Europe at the dawn of agriculture.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!